Comparison of Serum Interleukin 10 Levels between Leprosy and Non-Leprosy Population
DOI:
https://doi.org/10.18196/mmjkk.v21i1.6514Keywords:
leprosy, interleukin 10 (IL-10)Abstract
Leprosy is a chronic granulomatous infectious disease that attacks the peripheral nerves, skin, and other organs. The cytokine IL-10 can deactivate macrophages, inhibit IL-12 production, which also inhibits IFN-ϒ production. IL-10 directly inhibits CD4+T cells and antigen-presenting cell (APC) function in cells infected with M. leprae. The purpose of this study was to determine the differences in IL-10 levels in leprosy patients and non-patients at dr. Mohammad Hoesin Palembang Hospital. This study used a case-control design for comparing 2 groups. Respondents in this study were 80 people. The case samples were all leprosy patients who were treated at the dr. Mohammad Hoesin Hospital, Palembang for the period of January 16 - February 16, 2019, while the control group was medical personnel and paramedics who worked at the same hospital. The examination was carried out using the ELISA Sandwich method. The results showed that there was a significant difference in IL-10 levels between leprosy patients and non-leprosy leprosy (p=0.000). The average IL-10 level in leprosy patients (13.24 pg/ml) was lower than that in non-patients (40.15 pg/ml). It is concluded that there is a difference in IL-10 levels between leprosy patients and non-leprosy patients in leprosy sufferers are lower than non-leprosy persons.
References
REFERENCES
Jopling W.H. 2011.Hand Book of Leprosy. 5 th ed New Delhi:CBS. Published & Distributor. p.1-53, 92-100.
Kar H. Gupta R. Treatment of Leprosy. Clinics in Dermatolgy. 2015. 33: p.55-65.
Sandle T. Global Strategies for Elimination of Leprosy: A Review of Current Progress. J Anc Dis Prev Rem 2013.1: e112. Volume 1 • Issue 4 • 1000e112J Anc Dis Prev RemISSN:2329-8731 JADPR, an open access journal.
Sari, Amiruddin, Amin, Adam, Djamaluddin, Vitayani. Peran Interlukin -2 (IL-2), Interlukin-10 (IL-10) dan tumor necrosis factor-α (TNF-α) pada penyakit kusta. 2013. MDVI vol 40 No. I : 35-40.
Eva Krisna Sutedja, Jono Hadi Agusni, Hartati Purbo Dharmadji. Korelasi Kadar Interlukin-10 dengan Indeks Bakteri pada Pasien Kusta yang Telah Mendapat Pengobatan Multidrug Therapy (MDT). 2016. Vol 28
Kementerian Kesehatan RI Direktorat JenderalPengendalian Penyakit Dan PenyehatanLingkungan. 2012. Pedoman Nasional ProgramPengendalian Penyakit Kusta.
World Health Organization. Leprocy Update 2015: Time for action, accountabilityand Inclusionno. 35. 2016. Hal. 405–420.Apps. who.int/iris/bitsream/10665/249601/1/ WER9135.pdf.
Universal Elimination of Leprosy Plan Periode: 2016-2020. 1-10.
Pusat Data dan Informasi Kementrian Kesehatan Republik Indonesia. 2015: 18.
Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Buku Pedoman Nasional Pengendalian Penyakit Kusta.Jakarta: Departemen Kesehatan RI.2012
Lee. D.J, Rea. T.H, Modlin. R.L. Leprosy. In: Wolff. K., Goldsmith. L.A., Katz. S.I., Gilchrest. B.A., Paller. A.S., Leffell. D.J. 2012.editors. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: Mc Graw Hill companies. 2012. 2253-63.
Attia, EAS,. Abdallah, B., Khateeb, E., Saad,AA., Lotfi,RA., Abdallah, Shennawy,DE. Serum Th17 cytokines in leprosy:correlation with circulating CD4+CD25highFoxP3+ T-regs cells, as well asdown regulatory cytokine.,Arch Dermatol Res. 2014. 306: 793-801, DOI 10.1007/s00403-014-1486-2
Attia, EAS,. Abdallah, B., Khateeb, E., Saad,AA., Lotfi,RA., Abdallah, Shennawy,DE.Serum Th17 cytokines in leprosy:correlation with circulating CD4+CD25highFoxP3 + T-regs cells, as well asdown regulatory cytokine., Arch Dermatol. 2014. Res 306: 793-801, DOI 10.1007/s00403-014-1486-2.
Sanya Sharma, Naresh N Rai.Demographic profile and clinicopathologic concordance of leprosy in the North-West part of Rajasthan, India: A 2 years prospective study. Department of Pathology, Government Medical College, Kota, Rajasthan, India.2018. Vol 2 Issue 1 Page : 1-5
Marcela Romero-Montoya, Juan Camelo Beltran-Alzate, Nora Cardona-Castro. Evaluation and Monitoring of Mycobacterium leprae Transmission in Household Contacts of Patients with Hansen's Disease in Colombia. PLOS Neglected Tropical Diseases. 2017. DOI:10.1371/journal.pntd.0005325 January 23.
Moubasher MD, Kamel NA, Zedan Hatem, and Raheem DEA. Cytokines in leprosy II. Effect of treatment on serum cytokines in leprosy. Internasional Journal of Dermatology. 1998
Tomioka H. Immunology of leprosy-roles of cytokines in host defense against leprosy bacilli. In: Makino M, Matsuoka M, Goto M, Hatano K, editors. Leprosy science working toward dignity. 1st ed.Kanagawa: Tokai University. 2011. p.72-87
Downloads
Additional Files
Published
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
